0001493152-23-004898.txt : 20230214
0001493152-23-004898.hdr.sgml : 20230214
20230214161552
ACCESSION NUMBER: 0001493152-23-004898
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230211
FILED AS OF DATE: 20230214
DATE AS OF CHANGE: 20230214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Culley Brian M
CENTRAL INDEX KEY: 0001310683
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12830
FILM NUMBER: 23629517
MAIL ADDRESS:
STREET 1: 6725 MESA RIDGE ROAD
STREET 2: SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lineage Cell Therapeutics, Inc.
CENTRAL INDEX KEY: 0000876343
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943127919
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2173 SALK AVENUE
STREET 2: SUITE 200
CITY: CARLSBAD
STATE: CA
ZIP: 92008
BUSINESS PHONE: 5105213390
MAIL ADDRESS:
STREET 1: 2173 SALK AVENUE
STREET 2: SUITE 200
CITY: CARLSBAD
STATE: CA
ZIP: 92008
FORMER COMPANY:
FORMER CONFORMED NAME: BIOTIME INC
DATE OF NAME CHANGE: 19930328
4
1
ownership.xml
X0306
4
2023-02-11
0
0000876343
Lineage Cell Therapeutics, Inc.
LCTX
0001310683
Culley Brian M
2173 SALK AVENUE, SUITE 200
CARLSBAD
CA
92008
1
1
0
0
President and CEO
Common Shares, no par value
2023-02-11
4
M
0
31249
A
139143
D
Common Shares, no par value
2023-02-11
4
F
0
12744
1.35
D
126399
D
Restricted Stock Units
0.00
2023-02-11
4
M
0
31249
0.00
D
Common Shares
31249
93748
D
Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis.
Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options.
Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 31,249 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction.
The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter.
/s/ Brian M. Culley
2023-02-14